Glyukokortikoid-indutsirovannyy osteoporoz: istoricheskie aspekty i sovremennye podkhody k profilaktike i lecheniyu


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article presents some historical moments of the use of glucocorticoids in clinical practice, as well as new guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis. In 1950, a group of scientists, which included a rheumatologist Philip Hench, won the Nobel Prize in Physiology or Medicine «for discoveries concerning hormones of the adrenal cortex, their structure and biological effects». The first clinical use of glucocorticoids has been the starting point and marked the beginning of a new era in the treatment of rheumatic diseases. The recent recommendations of the American College of Rheumatology (2010) on the prevention and treatment of glucocorticoid-induced osteoporosis are analyzed in detail. The recommendations were developed taking into account the age groups, as well as the presence or absence of osteoporotic fractures. The development of clinical guidelines aimed at improvement of understanding of the problems of glucocorticoid-induced osteoporosis and improvement of methods of treatment and prevention of this condition.

全文:

受限制的访问

作者简介

I. Golovach

Email: golovachirina@yandex.ru

参考

  1. Баранова И.А. Глюкокортикоидиндуцированный остеопороз: патогенез, профилактика, лечение. Совр. ревматол. 2008;1:31-40.
  2. Головач И.Ю. Глюкокортикоїд-індукований остеопороз: стан проблеми і перспективи. Ліки України. 2006;104:15-23.
  3. Лесняк О.М., Баранова И.А., Торопцова Н.В. Клинические рекомендации «Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше». Ярославль, 2013. 48 с.
  4. Насонов Е.Л. Глюкокортикоидный остеопороз: современные рекомендации. Consilium medicum. 2002;4:8-13.
  5. Насонов Е.Л., Скрипникова И.А. Остеопороз при ревматических заболеваниях: роль глюкокортикоидов. Клин. медицина. 1997;10:12-8.
  6. Насонов Л.Е. Глюкокортикоиды: 50 лет применения в ревматологии. Тер. архив. 1999;5:5-9.
  7. Поворознюк В.В., Нейко Є.М., Головач І.Ю. Глюкокортикоїд-індукований остеопороз. К., 2000. 208 с.
  8. Alesci S., De Martino M.U., Gold P.W, Chrousos G.P. Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects. Neuroimmunomodulation. 2006;12(1):1-19.
  9. Angeli A., Guglielmi G., Dovio A., et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006; 39:253-59.
  10. Boland E.W., Headley N.E. Management of rheumatoid arthritis with smaller (maintenance) doses of cortisone acetate. J. Am. Med. Assoc. 1950;144:365-72.
  11. Compston J. Management of glucocorticoid-induced osteoporosis. Nat. Rev. Rheumatol. 2010;6(2):82-8.
  12. Cushing H.W. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull. Johns Hopkins Hosp. 1932;50:137-95.
  13. Dore R.K. How to prevent glucocorticoid-induced osteoporosis. Cleve. Clin. J. Med. 2010;77(8):529-36.
  14. Grossman J.M., Gordon R., Ranganath V.K., Deal C., Caplan L., Chen W., Curtis J.R., Furst D.E., McMahon M., Patkar N.M., Volkmann E., Saag K.G. American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoidlnduced Osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515-26.
  15. HenchPh.S.,Kendall E.C.,Slocumb C.H.,Polley H.F. The effect of hormone of the adrenal cortex,cortisone (17-hydroxy-II-dehydrocorticoster-one: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis and acute rheumatic fever. Trans. Assoc. Am. Physicias. 1949;62:64-80.
  16. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis Int. 2011;22(3):809-16.
  17. Lukert B.P. Glucocorticoid-induced osteoporosis. South Med. J. 2000;85 (2):48-51.
  18. Mazziotti G., Angeli A., Bilezikian J.P., Canalis E., Giustina A.Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2006;17(4):144-49.
  19. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 2005;115 (12):3318-25.
  20. Saag K.G., Gehlbach S.H., Curtis J.R., Youket T.E., Worley K., Lange J.L.Trends in prevention of glucocorticoid-induced osteoporosis. J. Rheumatol. 2006;33:1651-57.
  21. Tanaka Y. Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid inducedosteoporosis. Clin.Calcium. 2014;24 (9):1371-78.
  22. van Staa T.P. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006;79(3):129-37.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2015
##common.cookie##